10.24

4.49% 0.44

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $10.24, with a volume of 1.32M. It is up +4.49% in the last 24 hours and down -26.49% over the past month. Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Previous Close:

$9.80

Open:

$9.65

24h Volume:

1.32M

Relative Volume:

1.49

Market Cap:

$750.92M

Revenue:

$54.55M

Net Income/Loss:

$-193.57M

P/E Ratio:

-3.5433

EPS:

-2.89

Net Cash Flow:

$-181.86M

1W Performance:

+16.23%

1M Performance:

-26.49%

6M Performance:

-58.58%

1Y Performance:

-27.27%

1-Day Range:

$9.52

$10.27

1-Week Range:

$8.60

$10.27

52-Week Range:

$8.18

$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(415) 660-5320

Address

1700 OWENS STREET, SUITE 205, SAN FRANCISCO

Employee

286

Twitter

Next Earnings Date

2025-04-09

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	10.24	750.92M	54.55M	-193.57M	-181.86M	-2.89
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

Apr 19, 2025

Wasatch Advisors LP Has $11.29 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 19, 2025

Fmr LLC Grows Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 19, 2025

Apr 18, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Trexquant Investment LP - MarketBeat

Apr 18, 2025

(NRIX) Technical Data - news.stocktradersdaily.com

Apr 18, 2025

Apr 17, 2025

Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod - Investing.com Canada

Apr 17, 2025

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha

Apr 17, 2025

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st

Apr 17, 2025

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownShould You Sell? - MarketBeat

Apr 17, 2025

Nurix Therapeutics (NRIX) Advances Experimental Drug Following FDA Clearance - GuruFocus

Apr 17, 2025

Nurix gets FDA nod to begin trial for its anti-inflammatory drug - Seeking Alpha

Apr 17, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat

Apr 17, 2025

FDA Clears IND for Nurix's (NRIX) IRAK4 Degrader, Phase 1 Trial Set for 2025 | NRIX Stock News - GuruFocus

Apr 17, 2025

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479a Novel IRAK4 Degrader for Inflammatory Conditions - The Manila Times

Apr 17, 2025

Nurix Therapeutics Announces FDA Clearance for GS-6791/NX-0479 IND, Phase 1 Trials Set to Begin in Q2 2025 in Collaboration with Gilead Sciences - Nasdaq

Apr 17, 2025

FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight - Stock Titan

Apr 17, 2025

Apr 16, 2025

Vanguard Group Inc. Boosts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 15, 2025

Apr 14, 2025

Wells Fargo & Company Issues Pessimistic Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat

Apr 14, 2025

Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $35.00 at Stifel Nicolaus - MarketBeat

Apr 14, 2025

Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 14, 2025

Needham & Company LLC Issues Pessimistic Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat

Apr 14, 2025

Nurix Therapeutics (NASDAQ:NRIX) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat

Apr 14, 2025

Apr 13, 2025

ExodusPoint Capital Management LP Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 13, 2025

Apr 12, 2025

Nurix Therapeutics (NASDAQ:NRIX) Sets New 52-Week LowTime to Sell? - MarketBeat

Apr 12, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listin - GuruFocus

Apr 12, 2025

Apr 11, 2025

Polymer Capital Management HK LTD Purchases New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 11, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 11, 2025

Nurix Therapeutics Strengthens Workforce: 16 New Employees Receive Strategic Equity Awards - Stock Titan

Apr 11, 2025

160,500 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Springhill Fund Asset Management HK Co Ltd - MarketBeat

Apr 11, 2025

Q1 EPS Estimate for Nurix Therapeutics Increased by Analyst - MarketBeat

Apr 11, 2025

Nurix Therapeutics (NRIX) Sees Price Target Reduction Amid Ongoi - GuruFocus

Apr 11, 2025

Apr 10, 2025

UBS Adjusts Price Target on Nurix Therapeutics to $30 From $35, Keeps Buy Rating - marketscreener.com

Apr 10, 2025

Wellington Management Group LLP Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Apr 10, 2025

Apr 09, 2025

Wells Fargo Sticks to Their Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail

Apr 09, 2025

Grains Bottom and Why - The Globe and Mail

Apr 09, 2025

Nurix Therapeutics price target lowered to $25 from $32 at Wells Fargo - TipRanks

Apr 09, 2025

Nurix Therapeutics price target lowered to $35 from $36 at Stifel - TipRanks

Apr 09, 2025

28,564 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Bryce Point Capital LLC - MarketBeat

Apr 09, 2025

Apr 08, 2025

Nurix Therapeutics Q1 2025 Financial Highlights - TipRanks

Apr 08, 2025

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update | NRIX Stock News - GuruFocus

Apr 08, 2025